**Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Publications**


Neaton, JD, Kuller, LH. Diuretics Are Color Blind. *(JAMA* 2005;293:1663-1666)


**ALLHAT Abstracts and Presentations**

Listings are in ascending chronological order; through 2005.


Cushman WC, for the ALLHAT Research Group. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) - Design and initial characteristics. Presented at the 11th Scientific meeting of the Inter-American Society of Hypertension; Montréal, Quebec; June, 1995. *Hypertension* 1995;25:1356.

Grimm RH, Jr, for the ALLHAT Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Design and early baseline results. Presented at the 11th Asian-Pacific Congress of Cardiology; Bali, Indonesia; September, 1995.)

Cushman WC. Design and Aims of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Presented at the Panhellenic Congress on Arterial Hypertension; Greece; March, 1996.

UTSPH CCCT Bibliography Updated 22 Oct 07


Davis B, Proschan M, Ford CE, for the ALLHAT Research Group. Statistical design considerations for a large, simple trial of antihypertensive and lipid lowering treatments. Presented at the International Biometric Conference; Amsterdam, Netherlands; July 1-5, 1996.

Cushman WC. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Update on Southeastern Clinical Research. Presented at the 3rd Annual Meeting of the Consortium of Southeastern Hypertension Centers; Research Triangle Park, NC; August, 1996.

Davis BR, Proschan M, Ford CE, for the ALLHAT Research Group. Statistical issues in a large, simple trial of antihypertensive and lipid-lowering treatments. Presented at the American Statistical Association Meeting; Chicago, IL; August, 1996.


Grimm, RH. Regional differences in attainment of goal blood pressure (BP) amongst United States (US) treated hypertensives in ALLHAT. Presented by at the 17th Scientific Meeting of the International Society of Hypertension, Amsterdam, Netherlands, June 6-11, 1998.


Clinical Trials 2002; 23:77S.


Salive ME, ALLHAT results and future directions for hypertension research. (Presented at the American College of Preventive Medicine Meeting, February 22, 2003, San Diego, California.)

Wright J, AHT Results. (Presented at the Association of Black Cardiologist Meeting, March 30, 2003, Chicago, Illinois.)

Haywood J, LLT Results. (Presented at the Association of Black Cardiologist Meeting, March 30, 2003, Chicago, Illinois.)

Williamson J, ALLHAT: Results and implications in older ALLHAT patients. (Presented at the Society of Geriatric Cardiology Meeting, March 31, 2003, Chicago, Illinois.)


Leenen, F, ALLHAT Implications for hypertension in the elderly (Presented at the Canadian Geriatrics Society Annual Meeting, May 30-31, 2003, Ottawa, Canada.)

Alderman M, ALLHAT (Presented at the European Society of Hypertension Meeting, June 13-15 (14), 2003, Milan, Italy.)

Cushman W, for the ALLHAT Collaborative Research Group. Results of the ALLHAT trial: Antihypertensive trial results by baseline diabetic & fasting glucose status (Presented at the American Diabetes Association Scientific Sessions, June 13-17 [15th], 2003, New Orleans, Louisiana.)

Cushman W, ALLHAT vs. ANBP2. (Presented at the Southern Medical Association 7th Annual Conference on Hypertension, June 27-29 (28), 2003, Myrtle Beach, South Carolina.)

Wright J, Subgroup analysis of blacks and diabetics. (Presented at the National Medical Association Meeting, August 2-7, 2003, Philadelphia, Pennsylvania.)

Probstfield J, ALLHAT and JNC 7. (Presented at the European Society of Cardiology Meeting, August 30 - September 3, 2003, Vienna, Austria.)

Furberg C, ALLHAT Update. (Presented at Danish Society of Hypertension Meeting, September 25, 2003, Copenhagen, Denmark.)


Rahman M, Cardiovascular disease and renal disease outcomes in hypertensive patients with various levels of baseline renal function. (Presented at the American Association of Family Practitioners Meeting, October 4, 2003, New Orleans, Louisiana.)

Hassman J, Effects of ACE inhibitor and calcium channel blocker compared with diuretic in high-risk hypertensive person: Further results from ALLHAT (Presented at the American Osteopathic Association American College of Osteopathic Family Physicians Meeting, October 14, 2003, New Orleans, Louisiana.)

Cushman W, Metabolic syndrome & hypertension: ALLHAT – What ALLHAT did? (Presented at the Consortium for Southeastern
Hypertension Control Meeting, October 16-18, 2003, Coral Gables, Florida.)

Cushman W, Results from ALLHAT. (Presented to the Texas Chapter of the American Society of Hypertension, October 18, 2003, Houston, Texas.)

Leenen F, What have we learned from ALLHAT? (Presented at Canadian Cardiovascular Congress Meeting, October 25-29 (26), 2003, Toronto, Canada.

Davis BR, Hypertension treatment and diabetes. (Presented at the Chilean Society of Internal Medicine Meeting, October 28-29, 2003, Santiago, Chile.)

Davis BR, First step therapy for hypertension - ALLHAT. (Presented at the Chilean Society of Internal Medicine Meeting, October 28-29, 2003, Santiago, Chile.)

Davis BR, Heart failure, LVH, hypertension and treatment. (Presented at the Chilean Society of Internal Medicine Meeting, October 28-29, 2003, Santiago, Chile.)

Furberg C, ALLHAT: The key findings. (Presented at the 76th Annual Scientific Sessions of the American Heart Association, November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNC-VII Recommendations.)

Probstfield JL, ALLHAT results for subgroups and secondary outcomes (Presented at the 76th Annual Scientific Sessions of the American Heart Association, November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNC-VII Recommendations.)

Whelton PK, After NHANES, ALLHAT and JNC-VII: How can we implement the findings? (Presented at the 76th Annual Scientific Sessions of the American Heart Association, November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNC-VII Recommendations.)


Rahman M. Incidence of end stage renal disease (ESRD) and cardiovascular disease (CVD) in high risk hypertensive patients with reduced glomerular filtration rate (GFR). (Presented at the American Society of Nephrology Meeting, November 16, 2003, San Diego, California.)

Cutler J, ALLHAT: Main results and clinical implications. (Presented at the American Society of Health-System Pharmacists Meeting, December 9, 2003, New Orleans, Louisiana.)


Oparil S, Stroke results in ALLHAT. (Presented at the 29th Annual International Stroke Conference, February 5-7, 2004, San Diego, California.)

Alderman M, New data from ALLHAT. (Presented at the International Society of Hypertension Meeting, February 15-17, 2004, Sao Paulo, SP, Brazil.)


Williamson J, ALLHAT: Results and implications for older patients (Presented at the American Society of Hypertension Carolinas/Georgia Chapter Meeting, June 26, 2004, Hilton Head, South Carolina.)

Davis B. Heart failure results in ALLHAT (Presented at the European Society of Cardiology Scientific Sessions, August 28-September 1, 2004 [8/29], Munich, Germany.)

Kostis J, Preserved and impaired left ventricular systolic function in ALLHAT (Presented at the European Society of Cardiology Scientific Sessions, August 28-September 1, 2004 [9/1], Munich, Germany.)

Thadani T, Clinical outcomes in ALLHAT antihypertensive trial participants with type 2 diabetes, impaired fasting glucose, and normoglycemia. (Presented at the Canadian Cardiovascular Congress, October 23-27, 2004, Calgary, Canada.)

Leenen F, Heart failure results in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. (Poster presented at the Canadian Cardiovascular Congress, October 23-27, 2004, Calgary, Canada.)


Davis B, Clinical outcomes in ALLHAT antihypertensive trial participants with cardiovascular dysmetabolic syndrome (Presented at 77th Annual Scientific Sessions of the American Heart Association, November 7-10, 2004, New Orleans, Louisiana.)


Davis B, Cardiovascular and renal outcomes in patients with diabetes (Presented at the Blood Pressure Lowering Treatment Trialists’ Collaboration Symposium, June 16, 2005, Milan, Italy.)

Leenen F, Nwachuku MA, Cushman W, Black H, Simpson L, Davis B. Cardiovascular outcomes in hypertensives with CHD randomized to amlodipine versus lisinopril in ALLHAT. (Presented by William Cushman at European Society of Hypertension Scientific Sessions, June 17-21, 2005, Milan, Italy.)

Leenen F, Nwachuku MA, Cushman W, Black H, Simpson L, Davis B. Outcomes in high-risk hypertensives randomized to CCB vs, ACE inhibitor in ALLHAT. (Presented by William Cushman at European Society of Hypertension Scientific Sessions, June 17-21, 2005, Milan, Italy.)

Davis B, Absence of interaction between ADD1 Gly460Trp and antihypertensive drug on cardiovascular risk in hypertensive persons: The GenHAT Study (European Society of Hypertension, June 17-21[19], 2005, Milan, Italy.)

Black H, Davis B. Clinical outcomes in participants with metabolic syndrome in ALLHAT (Presented by Henry Black at European Society of Hypertension, June 17-21[19], 2005, Milan, Italy.)

Wright JT Jr, Davis BR, Black HR, for ALLHAT Collaborative Research Group. Clinical outcomes by race in non-diabetic participants with cardiovascular dysmetabolic syndrome in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (Oral presentation by Jackson Wright at ISHIB, July 15-19, 2005, San Juan, Puerto Rico.)


Specialized Program of Translational Research in Acute Stroke (SPOTRIAS) Publications


Cholesterol and Recurrent Events (CARE) Publications

Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project-a combined analysis of three large-scale randomized trials: Long-term Intervention with pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). *Am J Cardiol* 1995;76:899-905.


Wilt TJ, Davis BR, Meyers DG, Rouleau JL, Sacks FM. Prevalence and correlates of symptomatic peripheral atherosclerosis in individuals with coronary heart disease and cholesterol levels less than 240 mg/dl: baseline results from the Cholesterol and Recurrent Events (CARE) Study. *Angiology* 1996;47:533-541.

NITRODUR Publications


### Survival and Ventricular Enlargement (SAVE) Publications


Moye LA, Pfeffer MA, Braunwald E. Rationale, design and baseline characteristics of the survival and ventricular enlargement trial (SAVE). SAVE Investigators. Am J Cardiol 1991;68:70D-79D.


Systolic Hypertension in the Elderly Program (SHEP) Publications


Trial of Antihypertensive Interventions and Management Publications


Retinopathy of Prematurity (ROP; CRYO-, LIGHT-) Publications

Updated 22 Oct 07


Phelps DL, Phelps CE. Cryotherapy in infants with retinopathy of prematurity: a decision model for treating one or both eyes. *JAMA* 1989;261:1751-1756.


### Beta-Blocker Heart Attack Trial (BHAT) Publications


---

**Dietary Intervention Study of Hypertension (DISH) Publications**


**Hypertension Detection and Follow-up Program Publications**


Cooper SP, Ford CE, Hardy RJ, Davis BR, Hawkins CM, Labarthe DR (Letter to the Editor). Regarding "Goals of antihypertensive therapy: is there a point beyond which pressure reduction is dangerous?" Am J Hypertens 1990;3:733-734.


Curb JD, Labarthe DR, Cooper SP, Cutter GR, Hawkins CM. Training and certification of blood pressure observers. Hypertension 1983;5:610-614.


Curb JD, Hardy RJ, Labarthe DR, Borhani NO, Taylor JO. Reserpine and breast cancer in the HDFP. Hypertension 1982;4:307-311.


Davis BR, Langford HG, Blaufox MD, Curb JD, Polk BF, Shulman N. The association of postural changes in systolic blood pressure


HDFP Cooperative Group. Education level and five-year all cause mortality in the HDFP. Hypertension 1987;9:641-646.

HDFP Cooperative Group. Five-year findings of the HDFP: Prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension 1985;7:105-112.


HDFP Cooperative Group (Letter to the Editor). Hypertension Detection and Follow-up Program. JAMA 1980;244:1318.


Implications of the HDFP. *Prog Cardiovasc Dis* 1986;29:3-10.

Kraus JF, Conley A, Hardy RJ, Sexton M, Sweezy Z. Relationship of demographic characteristics of interviewers to blood pressure measurements. *J Comm Health* 1982;8:3-12.


Langford HG. Mortality at eight years for Hypertension Detection and Follow-up Program participants. In: Strasser T, Ganten D, editors. Mild Hypertension: From Drug Trials to Practice;1985 Dec 4-7; Konigstein, FRG. New York: Raven Press; 1987; p.45-52.


Schneider KA, Heyden S, Ford CE. Failure to reduce cholesterol as explanation for the limited efficacy of antihypertensive treatment in the reduction of CHD. Evidence from the HDFP. *Nephron* 1987;47(Suppl 1):104-107.


Smith EO, Curb JD, Hardy RJ, Hawkins CM, Tyroer HA. Clinic attendance in the HDFP. *Hypertension* 1982;4:710-715.


